Vir Biotechnology and GlaxoSmithKline announced Monday that the first patient was dosed last week in a phase 2/3 study on an antibody drug meant for the early treatment of COVID-19 in patients who are at high risk of hospitalization.
Fuente: Youtube
Vir Biotechnology and GlaxoSmithKline announced Monday that the first patient was dosed last week in a phase 2/3 study on an antibody drug meant for the early treatment of COVID-19 in patients who are at high risk of hospitalization.
Fuente: Youtube
